Clinical Oncology
Volume 21, Issue 2 , Pages 118-130 , March 2009

Optimising Care of Elderly Breast Cancer Patients: a Challenging Priority

  • K. Tipples
    • ,
  • A. Robinson

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: A. Robinson, Oncology Department, Southend University Hospital NHS Foundation Trust, Prittlewell Chase, Westcliff-on-Sea, Essex SS0 0RY, UK. Tel: +44-1702-435555; Fax: +44-1702-221039.

Received 2 June 2008 ,Revised 24 October 2008 ,Accepted 21 November 2008.

References 

  1. Tyczynski JE, Plesko I, Areleid A, et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer. 2004;112:1056–1064
  2. Sweeney C, Blair CK, Anderson KE, et al. Risk factors for breast cancer in elderly women. Am J Epidemiol. 2004;160:868–875
  3. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients?. J Clin Oncol. 2000;18:1709–1717
  4. Siegelmann-Danieli N, Khandelwal V, Wood CG, et al. Breast cancer in elderly women: outcome as affected by age, tumour features, comorbidities and treatment approach. Clin Breast Cancer. 2006;7:59–66
  5. Aapro M, Johnson CD. The elderly: geriatric oncology finally deserving adequate attention. Eur J Cancer. 2007;43:2312–2314
  6. Balducci L, Schonwetter R, Gray J, et al. Individualised treatment of the older cancer patient: a decision analysis. J Am Geriatr Soc. 1990;58:61a
  7. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–237
  8. Hogan DB, Ebly EM, Fung TS. Disease, disability, and age in cognitively intact seniors: results from the Canadian study of health and aging. J Gerontol. 1999;54A:M77–M82
  9. Daily Telegraph. 2 February 2008;
  10. Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer. 2007;43:1514–1528
  11. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841–845
  12. Yancik R, Lies LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–136
  13. Yancik R, Ganz PA, Varricchio CG, et al. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147–1157
  14. Enger SM, Thwin SS, Buist DSM, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol. 2006;24:4377–4383
  15. Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:151–156
  16. Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol. 2003;46:121–126
  17. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636–4642
  18. Diab SG, Elledge RM, Clark GM. Tumour characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–556
  19. Freyer G, Braud A-C, Chaibi P, et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the ‘Observatory on Elderly Patients’. Ann Oncol. 2006;17:211–216
  20. Balducci L, Wallace C, Khansur T, et al. Nutrition, cancer and aging: an annotated review. J Am Geriatr Soc. 1986;34:127–136
  21. Aslani A, Smith RC, Allen BJ. The predictive value of body protein for chemotherapy induced toxicity. Cancer. 2000;88:796–803
  22. Golledge J, Wiggins JE, Callam MJ. Age related variation in treatment and outcomes of patients with breast carcinoma. Cancer. 2000;88:369–374
  23. Cheung KL, Morgan DAL, Wong AWS, et al. Pattern of oestrogen receptor (ER)-positivity in elderly breast cancer: comparison with younger age. 10th Nottingham International Breast Cancer Conference, September 2007; abstract 0–35.
  24. Wyld L, Reed M. The role of surgery in the management of older women with breast cancer. Eur J Cancer. 2007;43:2253–2263
  25. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4534
  26. Wils JA, Bliss JM, Marty M, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999;17:1988–1998
  27. Nuzzo F, Perrone F, Labonia V, et al. Weekly docetaxel vs. CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial. 14th European Cancer Conference, Barcelona, September 2007; poster 2034.
  28. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21:35–40
  29. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med. 1999;341:2061–2067
  30. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2001;83:378–382
  31. Biganzoli L, Goldhirsch A, Straehle C, et al. Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group. Ann Oncol. 2004;15:207–210
  32. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–1587
  33. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol. 2002;20:494–502
  34. Muss HB, Biganzoli L, Sargent DJ, et al. Adjuvant therapy in the elderly. Making the right decision. J Clin Oncol. 2007;25:1870–1875
  35. Maas HAAM, Janssen-Heijnen MLG, Olde Rikkert MGM, et al. Comprehensive geriatric assessment and its clinical impact on oncology. Eur J Cancer. 2007;43:2161–2169
  36. Gosney M. Contribution of the geriatrician to the management of cancer in older patients. Eur J Cancer. 2007;43:2153–2160
  37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  38. Biganzoli L, Licitra S, Claudino W. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients – a jungle?. Eur J Cancer. 2007;43:2270–2278
  39. Nabholtz JM, Gligorov J. The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. Rev Recent Clin Trials. 2006;1:237–249
  40. Baum M, Budzar AU, Cuzick J, et al. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139
  41. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years of tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007;369:559–570
  42. Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98. J Clin Oncol. 2007;25:486–492
  43. Muss HB, Tu D, Ingle JN, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26:1948–1955
  44. Pritchard KI. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol. 2005;23:4850–4852
  45. De Boer R, Burris H, Monnier A, et al. on behalf of the H2H trial steering committee. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol. 2006;24(18S):582s;(abstract 10672)
  46. Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab. 2006;20(Suppl 1):S5–S13
  47. Mamounas EP, Lembersky B, Jeong JH, et al. NSABP-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease free survival in postmenopausal women with hormone receptor breast cancer. Clin Breast Cancer. 2006;7:416–421
  48. Punglia RS, Burstein HJ, Winer EP, et al. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modelling analysis. J Natl Cancer Inst. 2008;100:642–648
  49. Endocrine±Surgical Therapy for Elderly women with Mammary cancer: the ESTEeM trial. Protocol version 2.0 (5 December 2006).
  50. Miller ER, Krause A, Evans DB, et al. Phenotypes for endocrine resistance can by identified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response. Breast Cancer Res Treat. 2005;94(Suppl 1):S17;abstract 31
  51. Semiglazov VF, Semiglazov V, Ivanov V, et al. The relative efficacy of neoadjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol. 2004;22:519
  52. Renshaw L, Murray J, Young O, et al. Is there an optimal duration of neoadjuvant therapy?. Breast Cancer Res Treat. 2004;88(Suppl 1):S36
  53. Smith I, Dowsett M, on behalf of IMPACT Trialists . Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in post-menopausal women: the IMPACT trial. Breast Cancer Res Treat. 2003;82(Suppl 1):S6
  54. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532
  55. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumour proliferation more effectively than tamoxifen, independent of HER1/2 expression status. Cancer Res. 2003;63:6523–6531
  56. Kuter I, Hegg R, Singer CF, et al. On behalf of the NEWEST investigators. Fulvestrant 500mg vs 250mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. 30th Annual San Antonio Breast Cancer Symposium, 2007;abstract 23.
  57. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395
  58. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403
  59. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. A prospective combined analysis of two multicentre trials. Cancer. 2003;98:229–238
  60. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. A prospectively planned combined survival analysis of two multicentre trials. Cancer. 2005;104:236–239
  61. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–1670
  62. Sainsbury R, on behalf of the ATAC Trialists Group. Anastrozole shows greater carryover effects compared with tamoxifen and resolution of fracture risk post treatment — data from ATAC at 100 months' median follow up. European Breast Cancer Conference, 2008;poster 263.
  63. Ellis G, Bone HG, Chlebowski R, et al. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for nonmetastatic breast cancer. 30th Annual San Antonio Breast Cancer Symposium 2007; abstract 47.
  64. Schilder CM, Eggens PC, Boogerd W, et al. Neuropsychological sequelae of tamoxifen and exemestane after AC-chemotherapy in postmenopausal women with early breast cancer. Program and abstracts of the American Society of Clinical Oncology Annual Meeting, 2007;abstract 566.
  65. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995–998
  66. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651–2662
  67. Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  68. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  69. Muss HB, Tu D, Ingle JN, et al. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat. 2006;100(Suppl 1):S23;abstract 102
  70. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004;40:1170–1178
  71. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51:395–402
  72. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol. 1996;19:371–374
  73. Repetto L, Simoni C, Venturino A, et al. Mitoxantrone in elderly women with advanced breast cancer: a phase 2 study. Anticancer Res. 1995;15:2297–3000
  74. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004;22:4622–4630
  75. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–5387
  76. Muss HB, Berry DL, Cirrincione C, et al. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer patients aged 65 and older: results of CALGB/CTSU 49907. J Clin Oncol. 2008;26:abstract 507
  77. Slamon D, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. 30th Annual San Antonio Breast Cancer Symposium, 2007;abstract 13.
  78. Stockler M, Sourjina T, Grimison P, et al. ANZ Breast Cancer Trials Group. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). ASCO Annual Meeting Proc. 2007;25(18S):1031
  79. O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomised phase 2 study of capecitabine versus CMF as first line chemotherapy of breast cancer in women aged >55 years. Proc Am Soc Clin Oncol. 1998;103:abstract 398
  80. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23:2155–2161
  81. Feher O, Vodvarka P, Jassem J, et al. First line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicentre, randomised phase 3 study. Ann Oncol. 2005;16:899–908
  82. Rossi A, Gridelli C, Gebbia V, et al. Single agent vinorelbine as first line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res. 2003;23:1657–1664
  83. Basso U, Fratino L, Brunello A, et al. Which benefit from adding gemcitabine to vinorelbine in elderly (>70 years) women with metastatic breast cancer? Early interruption of a phase 2 study. Ann Oncol. 2007;18:58–63
  84. Debled M, Madranges N, Mertens C, et al. Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer. 6th European Breast Cancer Conference, 2008; poster 415.
  85. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18–24
  86. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology. 2000;14:221–227
  87. Monfardini S, Gridelli C, Pasetto LM, et al. Vulnerable and frail elderly: an approach to the management of the main tumour types. Eur J Cancer. 2008;44:488–493
  88. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34
  89. Zielinski CC, Awada A, Cameron DA, et al. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer. 2008;44:353–365
  90. Aapro M, Schwenkglenks M, Lyman G, et al. Reduced incidence of febrile neutropenia and related complications in elderly breast cancer patients receiving chemotherapy with pegfilgrastim primary prophylaxis versus current practice neutropenia management — results from an integrated analysis. 30th Annual San Antonio Breast Cancer Symposium, 2007; poster 1088.
  91. Body J-J, Coleman R, Clezardin P, et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer. 2007;43:852–858
  92. Aapro M, Abrahamsson PA, Body JJ. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420–432
  93. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34(Suppl 1):S3–S18
  94. Doyle JJ, Neugut AI, Jacobson JS. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–8605
  95. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–3815
  96. Kutteh LA, Hobday T, Jaffe A, et al. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer. J Clin Oncol. 2007;25(18 Suppl):22s
  97. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol. 2007;25(18 Suppl):964s
  98. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol. 2008;26:1231–1238
  99. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–3865
  100. Perez EA, Byrne J, Hammond I. Cardiac safety experience in 3558 patients treated with lapatinib. Ann Oncol. 2006;17(Suppl 9):ix70
  101. Baxter NN, Durham SB, Phillips KA, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the effects of chemotherapy. 30th Annual San Antonio Breast Cancer Symposium, 2007; poster 1075.
  102. Cameron D, Casey M, Press M, et al. A phase III randomised comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on tratsuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;Jan 11;(Epub ahead of print)
  103. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  104. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  105. SofEA (Study of Faslodex, Exemestane and Arimidex). Trial protocol, version 6 (17 November 2006).
  106. de Vries M, van Weert JC, Jansen J, et al. Step by step development of clinical care pathways for older cancer patients: necessary or desirable?. Eur J Cancer. 2007;43:2170–2178

PII: S0936-6555(08)00454-8

doi: 10.1016/j.clon.2008.11.015

Clinical Oncology
Volume 21, Issue 2 , Pages 118-130 , March 2009

Article Tools

* Image Usage & Resolution